^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MVA-BN-Brachyury IV vaccine

    i
    Other names: MVA-BN-Brachyury IV vaccine
    Associations

    News

    Trials
    Company:
    Bavarian Nordic
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3years
    Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. (PubMed, J Immunother Cancer)
    Intravenous administration of MVA-BN-brachyury-TRICOM vaccine was safe and tolerable. Maximum tolerated dose was not reached. The maximum administered dose was 10 infectious units every 3 weeks for three doses. This dose was selected as the recommended phase 2 dose.
    Clinical • P1 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    BN-Brachyury • MVA-BN-Brachyury IV vaccine
    over3years
    A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=13, Completed, Bavarian Nordic | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor)
    |
    ALK fusion • ER positive + PGR positive • PGR positive
    |
    MVA-BN-Brachyury IV vaccine
    almost4years
    A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Bavarian Nordic | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor)
    |
    ALK fusion • ER positive + PGR positive • PGR positive
    |
    MVA-BN-Brachyury IV vaccine
    almost5years
    A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Bavarian Nordic | Trial completion date: Nov 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Dec 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor)
    |
    ALK fusion • ER positive + PGR positive • PGR positive
    |
    MVA-BN-Brachyury IV vaccine